scholarly journals Transduction of Nonhuman Primate Brain with Adeno-Associated Virus Serotype 1: Vector Trafficking and Immune Response

2009 ◽  
Vol 20 (3) ◽  
pp. 225-237 ◽  
Author(s):  
Piotr Hadaczek ◽  
John Forsayeth ◽  
Hanna Mirek ◽  
Keith Munson ◽  
John Bringas ◽  
...  
2008 ◽  
Vol 0 (ja) ◽  
pp. 081212071307053
Author(s):  
Piotr Hadaczek ◽  
John Forsayeth ◽  
Hanna Mirek ◽  
Keith Munson ◽  
John Bringas ◽  
...  

2012 ◽  
Vol 23 (8) ◽  
pp. 891-902 ◽  
Author(s):  
Ernesto A. Salegio ◽  
Lluis Samaranch ◽  
Russell W. Jenkins ◽  
Christopher J. Clarke ◽  
Clementine Lamarre ◽  
...  

2014 ◽  
pp. 150127063140004
Author(s):  
Guo-jie Ye ◽  
Marina M Scotti ◽  
Darby L Thomas ◽  
Lijun Wang ◽  
David R. Knop ◽  
...  

2013 ◽  
Vol 87 (9) ◽  
pp. 4974-4984 ◽  
Author(s):  
B. Venkatakrishnan ◽  
J. Yarbrough ◽  
J. Domsic ◽  
A. Bennett ◽  
B. Bothner ◽  
...  

2004 ◽  
Vol 15 (8) ◽  
pp. 783-792 ◽  
Author(s):  
Yi-Lin Liu ◽  
Federico Mingozzi ◽  
Sol M. Rodriguéz-Colôn ◽  
Sasha Joseph ◽  
Eric Dobrzynski ◽  
...  

2014 ◽  
Vol 25 (3) ◽  
pp. 212-222 ◽  
Author(s):  
Mario Mietzsch ◽  
Sabrina Grasse ◽  
Catherine Zurawski ◽  
Stefan Weger ◽  
Antonette Bennett ◽  
...  

2021 ◽  
Vol 21 ◽  
Author(s):  
Wuh-Liang Hwu ◽  
Shin-Ichi Muramatsu ◽  
Bruria Gidoni-Ben-Zeev

: Preexisting immunity to adeno-associated virus (AAV) poses a concern in AAV vector–mediated gene therapy. Localized administration of low doses of carefully chosen AAV serotypes can mitigate the risk of an immune response. This article will illustrate the low risk of immune response to AAV serotype 2 vector–mediated gene therapy to the brain with support from clinical trial data in aromatic L-amino acid decarboxylase deficiency and Parkinson disease.


Sign in / Sign up

Export Citation Format

Share Document